@baldwidx, you posed a question (Post #: 71214630) in the "Market Capitalisation is a Better Valuation Metric Than Share Price" thread regarding
"(NNZ-)2591 is also "under development for stroke, peripheral neuropathy, memory impairment, cognitive impairment, traumatic brain injury, multiple sclerosis and Parkinson’s disease".
Jon Pilcher discussed at this forum that NEU has around 40 potential conditions for which NNZ-2591 is a potential treatment option. The limitation is bandwidth, and so the opportunities must be prioritised.
@baldwidx, you posed a question (Post #: 71214630) in the...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.27 |
Change
0.650(3.15%) |
Mkt cap ! $2.718B | |||
| Open | High | Low | Value | Volume |
| $20.84 | $21.56 | $20.76 | $7.760M | 364.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1378 | $21.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.29 | 218 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |